Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2017

View Archived Issues

Aptevo Therapeutics to sell hyperimmune commercial products to Saol Therapeutics

Fresenius Kabi closes acquisition of Merck KGaA's biosimilars business

Takeda and Noile-Immune Biotech enter a collaboration to advance next generation CAR-T cell therapy

GlaxoSmithKline, ViiV identify new HIV allosteric integrase inhibitors

ReViral begins dosing in phase IIa study of RV-521 for RSV

Promising RORgammaT inhibitors discovered at Merck & Co.

FDA places clinical hold on phase I studies of UCART-123

Increased SIRT4 expression linked to accelerated heart failure development

Novartis reports promising data from phase III study of fingolimod in pediatric MS

Enrollment completed in phase IIb study of BGS-649 for hypogonadotropic hypogonadism

PMV Pharmaceuticals describes novel compounds restoring mutant p53 function

Concert Pharmaceuticals presents new PPARalpha, PPARdelta agonists

Vanderbilt University divulges novel muscarinic acetylcholine M1 receptor modulators

Novel bile acid receptor agonists discovered at Alios BioPharma

Golden Biotechnology presents new compounds for liver cancer

First-in-human phase I results for (Z)-endoxifen in endocrine-refractory metastatic breast cancer

Axxam and Sanofi begin neurodegeneration research collaboration

Funding pledged to Global Antibiotic Research and Development Partnership

New phase I/II study investigates H3B-6545 in advanced ER-positive, HER2-negative breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...